Publications by authors named "M Geberth"

Claim this Profile
C
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Matthias Geberth

Breast· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Matthias Geberth

Breast· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Michael P Lux, Naiba Nabieva, Andreas D Hartkopf, Jens Huober, Bernhard Volz, Matthias Geberth

Cancers (Basel)· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Andreas D Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Matthias Geberth

Breast· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Andreas Schneeweiss, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth

Anticancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis